Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Breast

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Breast
III
Rexer, Brent
NCT02954874
ECOGBRES1418

Inherited CAncer REgistry (ICARE) Initiative

Miscellaneous

Miscellaneous
N/A
Pal, Tuya
NCT03231891
VICCMD1712

Olaparib with or without Atezolizumab in Treating Patients with Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer

Breast

This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection (locally advanced unresectable) or has spread to other places in the body (metastatic). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. It is not known whether giving olaparib with or without atezolizumab will work better in patients with non-HER2-positive breast cancer.
Breast
II
Abramson, Vandana
NCT02849496
VICCBRE1727ET-CT

Long Term Follow-up for Early Detection of Lung Cancer in Current or Former Smokers

Lung

This research trial studies the long term follow-up for early detection of lung cancer in current or former smokers. Following up on smokers by collecting and analyzing specimens in the laboratory, performing chest computed tomography (CT) scans, as well as reviewing medical records may help doctors detect lung cancer at an earlier stage.
Lung
N/A
Massion, Pierre
NCT03181256
VICCTHO1730

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study

Prostate

Prostate
N/A
Chang, Sam
VICCURO1734

Using Biomarkers and Imaging in Fungal Regions to Improve Lung Cancer Diagnosis

Lung

Lung
N/A
Grogan, Eric
VICCTHO1764

Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in First Complete Remission after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ruxolitinib phosphate works in treating older patients with acute myeloid leukemia in first complete remission after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Hematologic, Leukemia
II
Byrne, Michael
NCT03286530
VICCBMT1778

11C-Glutamine and 18F-FSPG PET Imaging in Diagnosing Patients with Metastatic Colorectal Cancer

Multiple Cancer Types

The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
Colon, Rectal
N/A
Manning, Henry
NCT03275974
VICCGI1781

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Bladder

This is a Phase II, open-label, single-arm, multicenter study of intravesical BCG plus ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. The study duration is 24 months.
Bladder
II
Chang, Sam
NCT03022825
VICCURO1784

Chemotherapy Levels in the Blood of Patients with Retinoblastoma

Retinoblastoma (Pediatrics)

Retinoblastoma (Pediatrics)
N/A
Daniels, Anthony
VICCREACH1792

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: